I-Mab Biopharma of Shanghai announced China approval to begin Phase I trials of its fully human CD47 mAb, which was developed to treat malignant tumors. Earlier this year, I-Mab was granted a similar approval in the US and reported the first patient dosing in June. I-Mab believes TJC4 has the potential to become a global best-in-class CD47 product because it binds to a unique epitope on CD47. This leads to minimal red blood cell binding, which allowed the molecule to avoid hemagglutination and anemia in preclinical tests. More details....
Share this with colleagues:
Original Article: I-Mab Ok'd to Start China Trials of CD47 Immunotherapy